Nonobese diabetic natural killer cells: A barrier to allogeneic chimerism that can be reduced by rapamycin

Transplantation

Volumn 92, Issue 9, 2011, Pages 977-984

  Al Adra, David P ^a,b   Chan, William F N ^a,b   Anderson, Colin C ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Allogeneic cell; Chimerism; Natural killer cell; Nonobese diabetic; Rapamycin

Indexed keywords

RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CELL STRUCTURE; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; DEPLETION; DRUG INHIBITION; FEMALE; IN VIVO STUDY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; NONOBESE DIABETIC MOUSE; NONOBESE DIABETIC NATURAL KILLER CELL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADAPTIVE IMMUNITY; ANIMALS; CHIMERISM; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELLS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED NOD; SIROLIMUS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 80055022647     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182313e70     Document Type: Article

References (65)

1. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400.
2. Chan WF, Perez-Diez A, Razavy H, et al. The ability of natural tolerance to be applied to allogeneic tissue: Determinants and limits. Biol Direct 2007; 2: 10.
3. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172: 603.
4. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187.
5. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9: 503.
6. Karre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2- deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675.
7. Karre K. How to recognize a foreign submarine. Immunol Rev 1997; 155: 5.
8. Warner JF, Dennert G. Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastasis in vivo. Nature 1982; 300: 31.
9. Murphy WJ, Kumar V, Bennett M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med 1987; 165: 1212.
10. Yoshino H, Ueda T, Kawahata M, et al. Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-scid mice. Bone Marrow Transplant 2000; 26: 1211.
11. Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980; 29: 1.
12. Li H, Kaufman CL, Ildstad ST. Allogeneic chimerism induces donorspecific tolerance to simultaneous islet allografts in nonobese diabetic mice. Surgery 1995; 118: 192.
13. Liang Y, Huang T, Zhang C, et al. Donor CD8+T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb. Blood 2005; 105: 2180.
14. Nikolic B, Takeuchi Y, Leykin I, et al. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes 2004; 53: 376.
15. Johansson SE, Hall H, Bjorklund J, et al. Broadly impaired NK cell function in non-obese diabetic mice is partially restored by NK cell activation in vivo and by IL-12/IL-18 in vitro. Int Immunol 2004; 16: 1.
16. Ogasawara K, Hamerman JA, Hsin H, et al. Impairment of NK cell function by NKG2D modulation inNODmice. Immunity 2003; 18: 41.
17. Ogasawara K, Hamerman JA, Ehrlich LR, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004; 20: 757.
18. Kataoka S, Satoh J, Fujiya H. Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity. Diabetes 1983; 32: 247.
19. Carnaud C, Gombert J, Donnars O, et al. Protection against diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex. J Immunol 2001; 166: 2404.
20. Poulton LD, Smyth MJ, Hawke CG, et al. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol 2001; 13: 887.
21. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180.
22. Shultz LD, Lang PA, Christianson SW, et al. NOD/LtSz-Rag1null mice: An immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J Immunol 2000; 164: 2496.
23. Suwanai H, Wilcox MA, Mathis D, et al. A defective Il15 allele underlies the deficiency in natural killer cell activity in nonobese diabetic mice. Proc Natl Acad Sci USA 2010; 107: 9305.
24. Belanger S, Tai LH, Anderson SK, et al. Ly49 cluster sequence analysis in a mouse model of diabetes: An expanded repertoire of activating receptors in the NOD genome. Genes Immun 2008; 9: 509.
25. Orr MT, Beilke JN, Proekt I, et al. Natural killer cells in NOD.NK1.1 mice acquire cytolytic function during viral infection and provide protection against cytomegalovirus. Proc Natl Acad Sci USA 2010; 107: 15844.
26. Gordon EJ, Wicker LS, Peterson LB, et al. Autoimmune diabetes and resistance to xenograft transplantation tolerance in NOD mice. Diabetes 2005; 54: 107.
27. Pearson T, Markees TG, Serreze DV, et al. Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J Immunol 2003; 171: 185.
28. Pearson T, Markees TG, Wicker LS, et al. NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes 2003; 52: 321.
29. Chan WF, Razavy H, Luo B, et al. Development of either split tolerance or robust tolerance along with humoral tolerance to donor and thirdparty alloantigens in nonmyeloablative mixed chimeras. J Immunol 2008; 180: 5177.
30. Eissens DN, Van Der Meer A, Van Cranenbroek B, et al. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype. Am J Transplant 2010; 10: 1981.
31. Luo H, Chen H, Daloze P, et al. Effects of rapamycin on human HLAunrestricted cell killing. Clin Immunol Immunopathol 1992; 65: 60.
32. Wai LE, Fujiki M, Takeda S, et al. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 2008; 85: 145.
33. Silver ET, Gong D, Hazes B, et al. Ly-49W, an activating receptor of nonobese diabetic mice with close homology to the inhibitory receptor Ly-49G, recognizes H-2D(k) and H-2D(d). J Immunol 2001; 166: 2333.
34. Anderson SK, Ortaldo JR, McVicar DW. The ever-expanding Ly49 gene family: Repertoire and signaling. Immunol Rev 2001; 181: 79.
35. Dimasi N, Biassoni R. Structural and functional aspects of the Ly49 natural killer cell receptors. Immunol Cell Biol 2005; 83: 1.
36. Kane KP, Silver ET, Hazes B. Specificity and function of activating Ly-49 receptors. Immunol Rev 2001; 181: 104.
37. Orr MT, Lanier LL. Inhibitory Ly49 receptors on mouse natural killer cells. Curr Top Microbiol Immunol 2011; 350: 67.
38. Pearson T, Shultz LD, Miller D, et al. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: A radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol 2008; 154: 270.
39. Nikolic B, Onoe T, Takeuchi Y, et al. Distinct requirements for achievement of allotolerance versus reversal of autoimmunity via nonmyeloablative mixed chimerism induction in NOD mice. Transplantation 2010; 89: 23.
40. Ruggeri L, Capanni M, Tosti A, et al. Innate immunity against hematological malignancies. Cytotherapy 2002; 4: 343.
41. Blazar BR, Taylor PA, Sehgal SN, et al. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood 1994; 83: 600.
42. Taylor PA, Lees CJ, Wilson JM, et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002; 100: 3400.
43. WuT, Sozen H, Luo B, et al. Rapamycin andTcell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy. Bone Marrow Transplant 2002; 29: 949.
44. Kieper WC, Jameson SC. Homeostatic expansion and phenotypic conversion of naive T cells in response to self peptide/MHC ligands. Proc Natl Acad Sci USA 1999; 96: 13306.
45. Cabatingan MS, Schmidt MR, Sen R, et al. Naive B lymphocytes undergo homeostatic proliferation in response to B cell deficit. J Immunol 2002; 169: 6795.
46. Hamby K, Trexler A, Pearson TC, et al. NK cells rapidly reject allogeneic bone marrow in the spleen through a perforin- and Ly49Ddependent, but NKG2D-independent mechanism. Am J Transplant 2007; 7: 1884.
47. Tiberghien P, Longo DL, Wine JW, et al. Anti-asialoGM1antiserum treatment of lethally irradiated recipients before bone marrow transplantation: Evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery. Blood 1990; 76: 1419.
48. Cho SG, Shuto Y, Soda Y, et al. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation. Exp Hematol 2004; 32: 1246.
49. Davenport C, Kumar V, Bennett M. Rapid rejection of H2k and H2k/b bone marrow cell grafts by CD8+ T cells and NK cells in irradiated mice. J Immunol 1995; 155: 3742.
50. Iizuka K, Scalzo AA, Xian H, et al. Regulation of the NK cell alloreactivity to bone marrow cells by the combination of the host NK gene complex and MHC haplotypes. J Immunol 2008; 180: 3260.
51. Pegram HJ, Andrews DM, Smyth MJ, et al. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 2011; 89: 216.
52. Kean LS, Hamby K, Koehn B, et al. NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation. Am J Transplant 2006; 6: 292.
53. Blazar BR, Hirsch R, Gress RE, et al. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment. J Immunol 1991; 147: 1492.
54. Chargui J, Moya MJ, Sanhadji K, et al. Anti-NK antibodies injected into recipient mice enhance engraftment and chimerism after allogeneic transplantation of fetal liver stem cells. Thymus 1997; 24: 233.
55. Beilke JN, Kuhl NR, Van Kaer L, et al. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat Med 2005; 11: 1059.
56. Lotzova E, Savary CA, Pollack SB. Prevention of rejection of allogeneic bone marrow transplants byNK1.1 antiserum. Transplantation 1983; 35: 490.
57. Raziuddin A, Longo DL, Mason L, et al. Differential effects of the rejection of bone marrow allografts by the depletion of activating versus inhibiting Ly-49 natural killer cell subsets. J Immunol 1998; 160: 87.
58. Barao I, Murphy WJ. The immunobiology of natural killer cells and bone marrow allograft rejection. Biol Blood Marrow Transplant 2003; 9: 727.
59. Westerhuis G, MaasWGE, Willemze R, et al. Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. Blood 2005; 106: 2215.
60. Raziuddin A, Bennett M, Winkler-Pickett R, et al. Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H2(b) bone marrow cell allografts. Blood 2000; 95: 3840.
61. Tamura F, Masuhara A, Sakaida I, et al. FK506 promotes liver regeneration by suppressing natural killer cell activity. J Gastroenterol Hepatol 1998; 13: 703.
62. Yanagihara RH, Adler WH. Inhibition of mouse natural killer activity by cyclosporin A. Immunology 1982; 45: 325.
63. Fried W, Kedo A, Barone J. Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma. Cancer Res 1977; 37: 1205.
64. Lucas CL, Workman CJ, Beyaz S, et al. LAG-3, TGF-beta, and cellintrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. Blood 2011; 117: 5532.
65. Nanji SA, Hancock WW, Luo B, et al. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes 2006; 55: 27.